India's Jubilant Signs Licensing Deal For US Pharma Firm's COVID-19 Drug

India's Jubilant Life Sciences Ltd said on Tuesday it had signed a non-exclusive licensing agreement for selling Gilead Sciences Inc's experimental COVID-19 treatment remdesivir in 127 countries,...

from NDTV News - Special https://ift.tt/3bqUqQ1